German ban on Ranbaxy's Dewas product expands to entire EU

The company said it has discontinued manufacturing of an injectable antibiotic at its Dewas plant.

EU lifts drug export ban from Ranbaxy's Toansa plant

European health regulator on Thursday lifted suspension imposed on export of drugs produced at Ranbaxy's Toansa plant to the EU stating medicines produced at the site posed no risk to public health despite having a number of manufacturing deficiencies.

Europeans find fault at Ranbaxy plant; say no public health risk

European regulators said on Thursday they have completed their assessment of manufacturing violations at Ranbaxy Laboratories Ltd`s facility in Toansa, India, and although deficiencies were found, they pose no risk to public health.

Andhra HC order not to impact merger with Ranbaxy: Sun Pharma

Last week, the court had vacated the status quo order it had issued earlier on the merger process between Sun Pharma and Ranbaxy.

Exports to EU from Ranbaxy's two plants to remain suspended

Exports from Ranbaxy plants at Toansa and Dewas to Europe will remain suspended as probes are continuing even as Indian authorities have withdrawn the certification of manufacturing standards from one of the units, European health regulator EMA said Wednesday.

Sun Pharma plans gradual phase-out of Ranbaxy drugs in US: Sources

Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States after completing a USD 3.2 billion takeover of its loss-making rival, sources with direct knowledge of the matter said.

Drugs sold by company in the Indian market are safe: Ranbaxy

Ranbaxy Laboratories on Friday insisted drugs sold by it in the Indian market are safe and effective and the company complies with country's regulations, even as the Supreme Court issued a notice to it.

SC notice to Ranbaxy over adulterated drugs

The Supreme Court on Saturday issued notice to Centre and Ranbaxy on a PIL seeking probe against the company for allegedly supplying adulterated drugs in the country.

Ranbaxy shares settle 1.51% down; m-cap erodes by Rs 43 cr

Shares of Ranbaxy Laboratories Monday settled for the day with losses of 1.51 percent, pursuant to which the market capitalisation of the company eroded by Rs 43 crore.

Ranbaxy slips almost 4% on US drug recall

Shares of Ranbaxy Laboratories slipped almost 4 percent Monday after the drug major recalled over 64,000 bottles of generic Lipitor in the US.

Ranbaxy faces more regulatory scrutiny after US ban

Ranbaxy Laboratories Ltd has been hit by more regulatory scrutiny sparked by a U.S. ban on the bulk of its drugs, in a backlash that could bump up compliance costs and erode profitability among some Indian makers of generic drugs.

Ranbaxy Laboratories hit again as US FDA bans more products

In a setback to Indian pharmaceutical giant Ranbaxy, the US has prohibited the company from producing and distributing drugs for the American market from its Toansa facility in Punjab.

Ranbaxy's Toansa plant under USFDA's scanner

Drug major Ranbaxy Laboratories Monday said the US health regulator has raised concerns over manufacturing practices at its Toansa plant in Punjab.

Ranbaxy under scanner of other regulators after USFDA alert

The regulators said action will be taken after assessing the FDA's reply.

Ranbaxy seeks to assuage shareholders' worries

Drug major Ranbaxy Laboratories Friday sought to assuage concerns of shareholders in the wake of company's stock price taking a hard knock after the US Food and Drug Administration banned the import of drugs from its Mohali plant.

Ranbaxy import ban: USFDA found suspected hair, oil in tablets

Tablets embedded with 'black fibre' that was suspected to be hair from an employee's arm, 'black spots' of oil from machines in tablets and absence of running water in toilets were some observations made by USFDA that has banned import of drugs made at Ranbaxy's Mohali unit.

Certain consent decree terms to apply to Mohali unit: Ranbaxy

"The FDA also ordered that the Mohali facility be subject to certain terms of the consent decree of permanent injunction entered against Ranbaxy in January 2012," according to United States Food and Drug Administration website.

US import alert on Ranbaxy; Mohali unit part of consent decree

"The firm will remain on the import alert until the company complies with U.S. Drug manufacturing requirements, known as current good manufacturing practices (CGMP)," USFDA said in a statement.

Ranbaxy falls about 30% after FDA import alert

A third Ranbaxy Laboratories plant in India has been sanctioned with an import alert ban from the US Food and Drug Administration, triggering the worst single day fall in its stock on Monday and a brokerage downgrade.

Ranbaxy facilities under review: Azad

Ranbaxy facilities in India are being reviewed after its US arm admitted to manufacturing certain drugs not in conformity with good manufacturing practices and which are considered "adulterated" under US law, Health Minister Gulam Nabi Azad said Tuesday.